Erythropoietin for Neonatal Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial.
Helen G Liley, Rod W Hunt, Rachel L O'Connell et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter randomized clinical trial evaluated the efficacy of erythropoietin (EPO) as an adjunct to therapeutic hypothermia in infants with moderate to severe hypoxic-ischemic encephalopathy (HIE). Conducted across 24 neonatal intensive care units, the study found no significant difference in the primary outcome of death or disability between the EPO group (34.1%) and the placebo group (28.7%), with a relative risk of 1.19 (95% CI, 0.84-1.68; P = .33).
Key findings
- EPO did not significantly reduce the composite outcome of death or disability compared to placebo (34.1% vs 28.7%).
- No significant differences were observed in secondary outcomes, including death (15.1% vs 12.1%).
- Safety outcomes were similar between the EPO and placebo groups, with no evident safety concerns.
Why it matters
Despite the potential for erythropoietin to improve outcomes in neonatal HIE, this study indicates it does not provide additional benefits when used alongside therapeutic hypothermia, which remains the standard care.